BioSenic (formerly Bone Therapeutics) uploaded a News Release
October 30, 2020
Bone Therapeutics Provides Third Quarter 2020 Business Update
- Manufacturing collaboration with Catalent to streamline future ALLOB production
- Catalent to acquire Bone Therapeutics’ cell therapy manufacturing facility for €12 million
- Exclusive license agreement with Link Health and Pregene for €55 million total in upfront and milestone payments to develop and commercialize ALLOB in Greater China and adjacent Asian countries
- Expansion of the product portfolio from orthopedics into inflammatory conditions